2009
DOI: 10.1111/j.1600-0404.2008.01068.x
|View full text |Cite
|
Sign up to set email alerts
|

Serum interleukin-6 is elevated in symptomatic carotid bifurcation disease

Abstract: Patients with symptomatic carotid atherosclerotic disease have elevated serum IL-6 levels compared with asymptomatic patients. Symptomatic patients have also more intense macrophage infiltration of the atherosclerotic plaque suggesting that inflammatory process may contribute to the destabilization of the carotid plaque.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

1
15
1
1

Year Published

2010
2010
2020
2020

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 33 publications
(18 citation statements)
references
References 44 publications
1
15
1
1
Order By: Relevance
“…The connection of high serum concentrations of IL-6 and TNF-α with the presence of unstable plaques assessed in ultrasound examinations has been confirmed by other authors as well [15, 25, 27]. In the present study, no significant differences in TNF-α serum levels depending on the presence of stenosis, its level or clinical manifestation were found, which is in agreement with the results obtained by other authors [23, 28]. …”
Section: Discussionsupporting
confidence: 93%
See 1 more Smart Citation
“…The connection of high serum concentrations of IL-6 and TNF-α with the presence of unstable plaques assessed in ultrasound examinations has been confirmed by other authors as well [15, 25, 27]. In the present study, no significant differences in TNF-α serum levels depending on the presence of stenosis, its level or clinical manifestation were found, which is in agreement with the results obtained by other authors [23, 28]. …”
Section: Discussionsupporting
confidence: 93%
“…Only some of them concern their participation in the development of atherosclerotic ICA stenosis [7, 8, 13, 15, 2326]. …”
Section: Discussionmentioning
confidence: 99%
“…2). Thus, the findings of the present study in an unselected population of CS subjects on contemporary pharmacotherapy are unable to confirm the clinical utility of several circulating biomarkers that have previously been suggested to indicate the symptomatic status of CS, including hsCRP,4,5 IL-6,4,21 Lp(a),4 and MMPs 4,6. Moreover, this analysis did not demonstrate the utility of several other classic (e.g., CD40L, sVCAM, fibrinogen, IL-1β, IL-8, IL-18, MPO, and MCP-1)4,11 and novel (e.g., visfatin and leptin/adiponectin)7,9,22 circulating biomarkers of atherosclerotic plaque destabilization and rupture.…”
Section: Discussioncontrasting
confidence: 91%
“…The clinical role of plasmatic biomarkers in the setting of carotid atherosclerosis has been extensively studied in these recent years [17][18][19] . This not only for the assessment of the embolic risk but also for the choice of the best type of carotid intervention [20][21][22] .…”
Section: Discussionmentioning
confidence: 99%